Modular Medical Completes Clinical Study of MODD1 Insulin Pump, Prepares for Next-Generation Pivot Launch
核心洞察
Modular Medical (搜索) successfully completed a clinical study of its MODD1 insulin pump involving nine clinicians with Type 1 diabetes (搜索) who provided real-world feedback for system refinements.
The study focused on testing ease of use for converting patients from multiple daily injections to the pump system, targeting the estimated $3 billion "almost-pumpers" market.
The company plans to submit its next-generation Pivot pump to the FDA for clearance in October 2025, incorporating improvements based on MODD1 study feedback.
Modular Medical (搜索) has successfully completed a clinical study of its MODD1 insulin pump, marking a significant milestone in the development of its next-generation diabetes (搜索) management technology. The study involved nine clinicians with Type 1 diabetes (搜索) who wore the MODD1 pump to provide real-world experience and feedback for the company's upcoming Pivot pump product.
Clinical Study Results and Objectives
The MODD1 study was specifically designed to test and refine the system's ease of use for converting patients from multiple daily injections to pump therapy. All participating clinicians currently use continuous glucose monitors and other insulin pumps, providing valuable comparative insights for the development team.
"We want to thank the clinicians who participated in this trial deployment for their time and feedback on our MODD1 pump, and we look forward to demonstrating improvements in usability when we repeat this trial with the Pivot," said Jeb Besser, CEO of Modular Medical (搜索).
The study represents a continuation of Modular Medical (搜索)'s efforts to validate its insulin delivery platform, following the first human use of the MODD1 pump announced earlier. The initial deployment involved a single clinician with Type 1 diabetes (搜索) under institutional review board approval from the FDA, as the reusable controller line required validation for human use.
Technology Platform and Market Focus
Modular Medical (搜索)'s approach centers on its patented insulin delivery technology, which the company describes as eliminating the tradeoff between complexity and efficacy. The MODD1 and upcoming Pivot pumps share identical controller modules, with the successful insulin delivery representing a key milestone in the platform's development.
The company specifically targets the estimated $3 billion "almost-pumpers" market with its user-friendly and affordable design. This market segment consists of adults with diabetes (搜索) who could benefit from pump therapy but have not adopted existing solutions due to complexity or cost barriers.
Regulatory Timeline and Next Steps
Based on the feedback and data collected from the MODD1 clinical study, Modular Medical (搜索) expects to submit its Pivot pump product to the U.S. Food and Drug Administration for clearance in October 2025. The Pivot represents the company's next-generation pump product, incorporating refinements identified through the MODD1 study.
The company's development strategy involves using the MODD1 study data to demonstrate improvements in usability when conducting future trials with the Pivot pump. This iterative approach allows for continuous refinement of the technology platform based on real-world clinical feedback.
Company Background and Leadership
Modular Medical (搜索) was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer who previously founded Tandem Diabetes (搜索) in 2005 and invented the t:slim insulin pump. The company's mission focuses on improving access to high-quality glycemic control for people with diabetes (搜索), extending beyond traditional "superusers" to provide "diabetes care for the rest of us."
As a development-stage medical device company trading on Nasdaq under the symbol MODD, Modular Medical (搜索) holds the distinction of having the first FDA-cleared patch pump designed specifically for the adult almost-pumpers market segment.